Q3 FY26 Results · Quarterly Results (Oct–Dec 2025)
Rossari Biotech:
₹32.8 Cr PAT. Margins Quietly Demolishing.
Now They’re Building a Factory in Saudi Arabia.
A specialty chemicals maker that makes soap, shampoo, and animal feed ingredients just turned the dial on its growth mode. They’re expanding capacity faster than a desi wedding celebration, launching Saudi Arabia ventures, and somehow doing all this while exporting to 50+ countries. All in a quarter’s work.
Market Cap₹2,197 Cr
CMP₹397
P/E Ratio15.9x
Div Yield0.12%
ROE12.2%
01 — At a Glance
The Soap Opera That Forgot to Write Bad Scripts
- 52-Week High / Low₹768 / ₹394
- Q3 FY26 Revenue₹581.7 Cr
- Q3 FY26 PAT₹32.8 Cr
- Q3 FY26 EPS₹5.92
- TTM EPS₹24.87
- Book Value / Share₹226
- Price to Book1.81x
- Total Assets (Sep 2025)₹2,088 Cr
- Return over 3 Months-29.9%
- Return over 5 Years-17.4%
Flash Summary: Rossari Biotech just announced Q3 FY26 revenues of ₹581.7 crore, up 13% YoY. PAT came in at ₹32.8 crore, growing just 3.4% YoY — not exactly fireworks. EBITDA margins compressed to 11.8% from 12%+. But wait, the board approved an in-principle greenfield manufacturing facility in Saudi Arabia, infused ₹8 million (₹8 crore equivalent) into its Saudi subsidiary, and is busy commissioning 30,000 MTPA of ethoxylation capacity. The stock is down 30% in 3 months and down 17% over 5 years. So investors are either panicking or sleeping through a transformation. Maybe both.
02 — Introduction
The Chemistry Nerd’s Dream Company That Nobody Talks About
Rossari Biotech was started in 2003. It’s one of India’s largest manufacturers of specialty chemicals. Three main categories: Home, Personal Care and Performance Chemicals (HPPC), which is their bread-and-butter; Textile Specialty Chemicals (TSC), where they compete with names most people can’t pronounce; and Animal Health and Nutrition (AHN), because apparently, making shampoo wasn’t enough — they also wanted to make your cattle look good.
The company manufactures 4,280+ products across 7 manufacturing units in Gujarat. They serve 1,000+ clients and distribute through 400+ distributors. They export to 50+ countries. So this is a company that’s been quietly building infrastructure for two decades while you were scrolling Instagram. Their instalation capacity is 332,100 MTPA — that’s the kind of number that makes a plant manager weep with joy.
Q3 FY26 is interesting because it tells a story: top-line growth of 13% is solid but not spectacular. Bottom-line growth of 3.4% is downright disappointing for an industrial company. Yet, management is confidently talking about new markets, new capacities, and now a greenfield plant in Saudi Arabia. The company is making its classic movie comeback — where the hero doesn’t look good in the middle chapters but is clearly heading somewhere important.
Management Clarity (Jan 2026 Concall): CEO Sunil Srinivasan Chari stated growth came from “volumes itself” — translation: they sold more stuff, prices didn’t move. EBITDA margin of 11.8% vs. normalized 15–16% was tied to “ongoing investments in capacity expansion, product development and market-seeding initiatives” plus higher employee costs. The message: margins will bounce back, but not today. Today is investment phase.
03 — Business Model: WTF Do They Even Make?
They Make The Chemicals You Don’t Know You’re Using Every Day
Members get full access to every article.
